Exelixis moves more products into clinical trials. Alnylam’s product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.
March 6, 2019
0
Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines with its new product XL092 entering clinical trials. The drug is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors & MET and was the subject of an active Investigational New Drug (IND) application the firm had submitted to the U.S. Food and Drug Administration (FDA) in December …